Human granulocytic anaplasmosis

Summary

Human granulocytic anaplasmosis (MONDO:0005118) is a disease and 2 clinical trials. A subtype of leukocyte disorder — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 2

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	human granulocytic anaplasmosis
Mondo ID	MONDO:0005118
EFO	EFO:0000777
MeSH	D000712
DOID	DOID:0050025
ICD-10-CM	A79.82
NCIT	C128425
SNOMED CT	13906002, 427481004, 85708001
UMLS	C0483368
MedGen	96911
GARD	0000071
Is cancer (heuristic)	no

Also known as: anaplasma caused disease or disorder · anaplasmoses · anaplasmosis · HGA · HGE · human anaplasmosis · human anaplasmosis caused by Anaplasma phagocytophilum · human ehrlichial infection, human granulocytic type · infection by Anaplasma phagocytophilum

Disease family

This is a subtype of leukocyte disorder. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › immune system disorder › leukocyte disorder › human granulocytic anaplasmosis

Related subtypes (22): human monocytic ehrlichiosis, B cell deficiency, leukopenia, B-cell neoplasm, dendritic cell sarcoma, T-cell leukemia, phagocyte bactericidal dysfunction, EBV-positive T-cell lymphoproliferative disorder of childhood, small intestinal enteropathy-associated T-cell lymphoma, pituitary gland basophil adenoma, leukostasis, mastocytosis, hereditary neutrophilia, Pelger-Huet anomaly, functional neutrophil defect, thymoma type B, POEMS syndrome, Langerhans cell histiocytosis, subcutaneous panniculitis-like T-cell lymphoma, eosinophil peroxidase deficiency, eosinophil disorder, mast cell activation syndrome

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 2.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT07312474	Not specified	RECRUITING	Epidemiological, Clinical and Biological Characteristics of Human Anaplasmosis Cases in Alsace
NCT01013636	Not specified	UNKNOWN	Human Anaplasmosis in Eastern France